<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-149610" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mohs Micrographic Surgery Chemoprophylaxis Options for Nicotinamide and Oral Retinoids </title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hunter</surname>
            <given-names>Abigail L.</given-names>
          </name>
          <aff>Campbell University/Sampson Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bermudez</surname>
            <given-names>Rene</given-names>
          </name>
          <aff>Sampson Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abigail Hunter declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rene Bermudez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-149610.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Nicotinamide and oral retinoids are medications used in non-melanoma skin cancer prophylaxis. Nicotinamide and retinoids are derivatives of vitamin B3 and vitamin A, respectively. Patients with a substantially increased risk of non-melanoma skin cancers include recipients of solid-organ transplants, those with certain genodermatoses, and individuals with extensive chronic sun damage. This activity reviews the indications, mechanisms of action, contraindications, and adverse event profiles for nicotinamide and oral retinoids as chemoprophylactic agents for non-melanoma skin cancer. This activity also highlights the role of the interprofessional team when caring for this patient population.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Correlate the mechanism of action of nicotinamide and oral retinoids with their application as chemoprophylactic agents in patients at increased risk of non-melanoma skin cancer.</p></list-item><list-item><p>Identify candidates for chemoprophylaxis with nicotinamide and oral retinoids based on the clinical history and presentation.</p></list-item><list-item><p>Employ best practices for monitoring patients for the adverse effects of nicotinamide and oral retinoids and recognize and manage these effects when they occur.</p></list-item><list-item><p>Develop and effectively apply interprofessional team strategies to improve outcomes for solid-organ transplant recipients requiring chemoprophylaxis against non-melanoma skin cancer.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=149610&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=149610">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-149610.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The Mohs surgeon should be familiar with nonsurgical options for treating nonmelanoma skin cancers (NMSCs) and medical options for preventing new skin cancer formation. Patients not well-suited for cutaneous surgery due to their overall clinical health can be offered alternative treatment modalities such as topical or systemic chemotherapy or radiation. Other patients with extensive sun exposure over the years, certain genodermatoses, chronic radiation exposure, and immunosuppression are at greater risk of developing NMSCs than patients without these risk factors.<xref ref-type="bibr" rid="article-149610.r1">[1]</xref>&#x000a0;In patients with increased risk factors, chemoprophylaxis, or agents used to slow the growth of NMSCs, can be utilized to prevent the formation of NMSCs and, subsequently, the associated morbidity and mortality.<xref ref-type="bibr" rid="article-149610.r1">[1]</xref></p>
        <p>Basal cell carcinoma (BCC) is the most prevalent NMSC in the United States, with an annual incidence of approximately 2 million.<xref ref-type="bibr" rid="article-149610.r2">[2]</xref>&#x000a0;Although death from BCC is rare, the tumors can be associated with significant morbidity and cost. The second most common NMSC, squamous cell carcinoma (SCC), has an annual incidence of approximately 700,000 cases in the United States, of which approximately 2% result in death.<xref ref-type="bibr" rid="article-149610.r3">[3]</xref>&#x000a0;In addition to preventing the morbidity and mortality associated with these NMSCs, there is evidence that preventative measures such as chemoprophylaxis save the healthcare system money. A study from 2015 analyzed the economic burden of skin cancer treatments&#x000a0;and found the average annual cost of skin cancer treatments increased from 2002-2006 to 2007-2011 from $3.6 billion to $8.1 billion.<xref ref-type="bibr" rid="article-149610.r4">[4]</xref>&#x000a0;Preventing new NMSC formation can reduce healthcare spending and patient morbidity and mortality.</p>
        <p>Nicotinamide and oral retinoids are&#x000a0;2 systemic chemoprophylactic medications used in populations at high risk of developing NMSCs. A survey sent to the American College of Mohs Surgeons found that 76.9% of the respondents recommend nicotinamide to their patients for NMSC prevention.<xref ref-type="bibr" rid="article-149610.r5">[5]</xref>&#x000a0;These&#x000a0;2 medications are essential tools the Mohs surgeon can utilize to decrease morbidity and mortality in patients with multiple NMSCs.</p>
      </sec>
      <sec id="article-149610.s3" sec-type="Function">
        <title>Function</title>
        <p>Nicotinamide is a form of water-soluble vitamin B3 available in both oral and topical formulations; the oral formulation has been demonstrated to decrease the rate of NMSC formation.<xref ref-type="bibr" rid="article-149610.r6">[6]</xref>&#x000a0;</p>
        <p>Nicotinamide plays an essential role in glycolysis by generating the NAD<sup>+ </sup>needed for ATP production and therefore is critical for generating cellular energy and influencing cellular metabolism.<xref ref-type="bibr" rid="article-149610.r7">[7]</xref>&#x000a0;By preventing cellular energy depletion, nicotinamide increases excisional DNA repair and prevents immunosuppression due to ultraviolet radiation (UVR).<xref ref-type="bibr" rid="article-149610.r1">[1]</xref></p>
        <p>Recommendations have been published in the Journal of the American Academy of Dermatology (JAAD) that support using nicotinamide 500 mg twice daily in patients with field cancerization or a history of more than one SCC.<xref ref-type="bibr" rid="article-149610.r8">[8]</xref><xref ref-type="bibr" rid="article-149610.r9">[9]</xref>&#x000a0;These recommendations are based on a randomized controlled trial in Australia that enrolled immunocompetent patients with more than two NMSCs into a nicotinamide arm and a placebo arm. This trial found a 23% decrease in SCCs and a 13% reduction in actinic keratoses (AKs) in patients taking nicotinamide 500 mg twice daily, followed over 1 year, compared to the patients taking a placebo.<xref ref-type="bibr" rid="article-149610.r10">[10]</xref>&#x000a0;This study did not find a significant decrease in new BCC formation in the nicotinamide group compared to the placebo group.<xref ref-type="bibr" rid="article-149610.r10">[10]</xref></p>
        <p>The same research group studied the use of nicotinamide in renal transplant recipients; however, this study was underpowered to assess the rate of SCC formation in this patient population.<xref ref-type="bibr" rid="article-149610.r11">[11]</xref>&#x000a0;A different research group published a randomized placebo-controlled trial in March 2023 that found that oral nicotinamide therapy over 1 year did not decrease NMSCs or AKs in immunosuppressed solid-organ transplant recipients.<xref ref-type="bibr" rid="article-149610.r12">[12]</xref>&#x000a0;Furthermore, a systematic review and meta-analysis were performed to analyze the effect of nicotinamide on skin cancer prophylaxis regardless of immunosuppression status. This analysis found moderate-quality evidence to support nicotinamide use for SCC prevention and low-quality evidence to support nicotinamide use for BCC prevention in general and organ-transplant-recipient populations.<xref ref-type="bibr" rid="article-149610.r13">[13]</xref></p>
        <p>Retinoids comprise natural and synthetic vitamin A analogs with multiple therapeutic uses in dermatology, including acne, psoriasis, and cutaneous T-cell lymphoma. Numerous topical and oral formulations of retinoids target retinoid nuclear receptors to exert their effects. The mechanism of action regarding retinoid chemoprophylaxis is poorly understood but likely represents a combination of factors, including immunomodulation, inhibition of cellular proliferation and keratinization, and induction of apoptosis.<xref ref-type="bibr" rid="article-149610.r14">[14]</xref></p>
        <p>The third-generation oral retinoid, acitretin, is well-established in the literature to prevent skin cancer formation in solid-organ transplant recipients and patients with diseases predisposing to UVR damage, like xeroderma pigmentosum. Isotretinoin, a first-generation oral retinoid, has a single documented case of its use in a kidney-transplant recipient. This patient was treated with 0.5 mg to 1.0 mg/kg/day with a subsequent reduction of new NMSCs by half over&#x000a0;2 months.<xref ref-type="bibr" rid="article-149610.r15">[15]</xref>&#x000a0;Although the use of isotretinoin in the transplant population is not well studied, it may be considered an alternative in patients who cannot tolerate acitretin due to renal insufficiency.<xref ref-type="bibr" rid="article-149610.r16">[16]</xref>&#x000a0;Isotretinoin has also been shown to decrease the incidence of NMSC in patients with xeroderma pigmentosum. Treatment with isotretinoin 2 mg/kg/day in these patients over&#x000a0;2 years resulted in a 63% decrease in NMSC formation in 5 of 7 patients.<xref ref-type="bibr" rid="article-149610.r17">[17]</xref><xref ref-type="bibr" rid="article-149610.r18">[18]</xref></p>
        <p>There is little evidence for using other oral retinoids in the chemoprevention of NMSCs. Oral alitretinoin is unavailable commercially in the United States and is primarily used for chronic eczema in Europe.<xref ref-type="bibr" rid="article-149610.r19">[19]</xref>&#x000a0;Bexarotene is primarily used for treating cutaneous T-cell lymphoma and has been used for lymphoproliferative disorders in organ-transplant recipients.<xref ref-type="bibr" rid="article-149610.r20">[20]</xref><xref ref-type="bibr" rid="article-149610.r21">[21]</xref></p>
        <p>A 2018 study recommends starting a patient on prophylactic acitretin if a patient has developed more than&#x000a0;5 SCCs over 2 to 3 years, the formation of at least&#x000a0;1&#x000a0;SCC of stage T2b/T3 or higher in combination with field photodamage, or field photodamage that is nonresponsive to 5-fluorouracil or photodynamic therapy.<xref ref-type="bibr" rid="article-149610.r9">[9]</xref>&#x000a0;In these patient populations, the authors recommend starting oral acitretin at 10 mg every other day with gradual dose increases as tolerated over a month until a final dose of 20 mg daily is reached.<xref ref-type="bibr" rid="article-149610.r9">[9]</xref></p>
      </sec>
      <sec id="article-149610.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>The&#x000a0;adverse effects of the chemoprophylactic agents should be weighed against their potential benefit to patients. Nicotinamide is a relatively safe medication since it is a form of water-soluble vitamin B3; excess&#x000a0;nicotinamide is excreted from the body. However, patients should be counseled to avoid the&#x000a0;readily available over-the-counter formulation of niacin, which can produce flushing.<xref ref-type="bibr" rid="article-149610.r22">[22]</xref>&#x000a0;There are over-the-counter formulations of nicotinamide available that avoid this effect. Additionally, nicotinamide can result in liver failure at doses greater than 3 g daily.<xref ref-type="bibr" rid="article-149610.r23">[23]</xref></p>
        <p>Topical retinoids primarily have localized adverse effects, including redness, dryness, pruritis, and peeling of the skin.<xref ref-type="bibr" rid="article-149610.r24">[24]</xref>&#x000a0;The adverse effects of oral retinoids are more systemic and potentially more severe when compared to topical retinoids. Oral retinoid therapy is teratogenic, affecting the developing fetal central nervous system, cardiovascular system, thymus, and face.<xref ref-type="bibr" rid="article-149610.r24">[24]</xref>&#x000a0;Although topical retinoid formulations do not appear to concentrate in plasma, even in applications beyond the recommended dose, many practitioners avoid topical retinoids during pregnancy.<xref ref-type="bibr" rid="article-149610.r25">[25]</xref> The potential teratogenic effects of retinoids used as chemoprophylaxis may be a lesser concern overall, as most patients requiring chemoprophylaxis are&#x000a0;beyond childbearing. However, it could still be relevant for a small subset of patients.</p>
        <p>Other effects of oral retinoids include dryness of mucous membranes, arthralgias, myalgias, bone pain, headaches, and night blindness.<xref ref-type="bibr" rid="article-149610.r24">[24]</xref>&#x000a0;Dryness of mucous membranes, especially cheilitis, is common and treated symptomatically. Evidence shows that retinoids affect bone metabolism, but studies conflict with whether the drugs decrease bone mineral density over time. However, skeletal hyperostosis and extraspinal calcification of ligaments and tendons can occur with oral retinoids.<xref ref-type="bibr" rid="article-149610.r26">[26]</xref>&#x000a0;Headaches associated with oral retinoids tend to be mild, but a high index of suspicion is warranted for pseudotumor cerebri if the headaches are severe and associated with visual symptoms. Additionally, concurrent use of retinoids and tetracyclines should be avoided since this class of drugs is also associated with pseudotumor cerebri.<xref ref-type="bibr" rid="article-149610.r27">[27]</xref></p>
        <p>Oral retinoids are also associated with elevated cholesterol, triglycerides, and liver enzymes.<xref ref-type="bibr" rid="article-149610.r24">[24]</xref>&#x000a0;The liver enzyme elevations typically peak between 2 and 8 weeks of therapy and then return to baseline. Current laboratory screening recommendations include baseline screening of complete blood count, creatinine, lipid panel, and liver enzymes. A lipid panel and liver enzymes should then be checked monthly for 1 to 2 months as the dose is escalated after therapy initiation and every&#x000a0;3 months once the patient has reached a stable dose.<xref ref-type="bibr" rid="article-149610.r24">[24]</xref><xref ref-type="bibr" rid="article-149610.r9">[9]</xref>&#x000a0;A meta-analysis found that isotretinoin causes an increase in both lipids and liver enzymes, but the mean changes were not high-risk.<xref ref-type="bibr" rid="article-149610.r28">[28]</xref>&#x000a0;If liver enzymes increase more than 3-fold of the upper limit of normal, it is advisable to discontinue the oral retinoid.<xref ref-type="bibr" rid="article-149610.r29">[29]</xref>&#x000a0;Alcohol use should be strongly discouraged in patients taking oral retinoids; it is associated with increased retinoid metabolism and subsequent hepatic toxicity and fibrosis.<xref ref-type="bibr" rid="article-149610.r30">[30]</xref></p>
        <p>Depression is an effect of oral retinoids that remains debated. Some literature suggests an association between oral retinoids and mood disorders; other sources indicate improved mood while on the medication, possibly due to improvement in the underlying cutaneous condition.<xref ref-type="bibr" rid="article-149610.r31">[31]</xref>&#x000a0;Patients undergoing oral retinoid therapy should be screened for depression and mood disorders and counseled about the possible association; the medication should be discontinued if symptoms arise during oral retinoid therapy.<xref ref-type="bibr" rid="article-149610.r24">[24]</xref></p>
        <p>Acitretin has been associated with poor wound healing, characterized by excessive granulation tissue formation and hypertrophic scarring. A study published in 2004 evaluating the surgical outcomes of solid-organ transplant patients taking acitretin did not find a significant difference in wound healing complications when compared to patients not taking the medication.<xref ref-type="bibr" rid="article-149610.r32">[32]</xref></p>
      </sec>
      <sec id="article-149610.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The patients most likely to need chemoprophylaxis for NMSCs are transplant recipients on immunosuppressive medications, people with certain genodermatoses, and patients with significant sun exposure over their lifetime. Since Mohs surgeons are likely to encounter more aggressive NMSCs in practice, they should be familiar with the risks unique to each of these populations and the appropriate management of NMSC chemoprophylaxis.</p>
        <p>According to the United Network for Organ Sharing, more than 42,800 organ transplants were performed in 2022. Solid-organ transplant recipients are estimated to have between 60 and 250 times the risk of developing an SCC and 10 to 40 times the risk of developing a BCC above the general population.<xref ref-type="bibr" rid="article-149610.r33">[33]</xref>&#x000a0;It is estimated that NMSCs cause approximately 3% of cancer-related deaths in the transplant population.<xref ref-type="bibr" rid="article-149610.r34">[34]</xref>&#x000a0;Most skin cancers will begin to develop within 8 years of transplant in younger patients but as early as&#x000a0;3 years in patients who undergo transplant after age 60.<xref ref-type="bibr" rid="article-149610.r35">[35]</xref><xref ref-type="bibr" rid="article-149610.r36">[36]</xref> Furthermore, the time interval between the formation of new skin cancers reduces with each subsequent occurrence following the appearance of the initial skin cancer. Additionally, the severity of the tumors correlates with the total number of skin cancers the patient has experienced.<xref ref-type="bibr" rid="article-149610.r37">[37]</xref>&#x000a0;SCCs also tend to be more aggressive in transplant recipients, with a recurrence rate of 13.4%.<xref ref-type="bibr" rid="article-149610.r38">[38]</xref></p>
        <p>The most important factor in NMSC development in this patient population is high UVR exposure before and after the transplant.<xref ref-type="bibr" rid="article-149610.r39">[39]</xref><xref ref-type="bibr" rid="article-149610.r33">[33]</xref>&#x000a0;Other predisposing factors to NMSC development include fair skin, aging, tobacco use, and infection with the Human papillomavirus.<xref ref-type="bibr" rid="article-149610.r33">[33]</xref>&#x000a0;These factors&#x000a0;must be considered when evaluating&#x000a0;the risk of NMSC in solid-organ transplant patients and&#x000a0;the timing of the initiation of chemoprophylaxis therapy.</p>
      </sec>
      <sec id="article-149610.s6" sec-type="Other Issues">
        <title>Other Issues</title>
        <p>Patients should be educated that discontinuing acitretin will rapidly return the rate of SCC formation to baseline.<xref ref-type="bibr" rid="article-149610.r40">[40]</xref>&#x000a0;Other potential chemoprophylaxis measures can be considered if acitretin is contraindicated or poorly tolerated. Other chemoprophylactic options include photodynamic therapy or topical chemoprophylaxis with retinoids, 5-fluorouracil, imiquimod, ingenol mebutate, or diclofenac.&#x000a0;Of these options, 5-fluorouracil and imiquimod have the strongest level of evidence for use.<xref ref-type="bibr" rid="article-149610.r9">[9]</xref></p>
        <p>The role of nicotinamide as chemoprophylaxis for melanocytic tumors seems plausible based on its mechanism of action but has not been confirmed in clinical trials.<xref ref-type="bibr" rid="article-149610.r41">[41]</xref>&#x000a0;However, there is some evidence that administration of N-acetylcysteine may reduce ultraviolet-induced oxidative stress in melanocytic nevi and thereby reduce long-term melanoma risk.<xref ref-type="bibr" rid="article-149610.r42">[42]</xref></p>
        <p>It is also well established that switching from a calcineurin inhibitor to a mechanistic target of rapamycin (mTOR) inhibitor reduces the number of NMSCs seen in both kidney and liver transplant recipients.<xref ref-type="bibr" rid="article-149610.r43">[43]</xref>&#x000a0;Communicating with the transplant physician and making appropriate drug regimen modification recommendations is important, especially if the patient has experienced multiple or high-risk NMSCs.</p>
      </sec>
      <sec id="article-149610.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Although some&#x000a0;Mohs surgeons will not medically manage high-risk patients,&#x000a0;they must understand which patients may benefit from chemoprophylaxis and work with the primary dermatologist to ensure they receive comprehensive care. Additionally, if the Mohs surgeon does manage high-risk patients with chemoprophylaxis, they should work alongside the transplant physician to ensure their medication regimen balances the role of organ anti-rejection and the development of malignancies. Many prospective randomized controlled trials have demonstrated that mTOR inhibitors like sirolimus reduce the incidence of SCCs in the organ transplant population.<xref ref-type="bibr" rid="article-149610.r44">[44]</xref><xref ref-type="bibr" rid="article-149610.r45">[45]</xref><xref ref-type="bibr" rid="article-149610.r46">[46]</xref>&#x000a0;</p>
        <p>Collaboration among healthcare professionals involved in the care of solid-organ transplant recipients&#x000a0;should also include&#x000a0;nurses and pharmacists. An interdisciplinary approach ensures comprehensive care, sharing of expertise, and better management of potential complications.&#x000a0;By implementing these strategies, the healthcare team can help reduce the risk of developing skin cancer in patients who have undergone solid-organ transplantation. Early detection, sun protection, regular monitoring, and comprehensive care are key to promoting the best possible outcomes and overall well-being for these patients.</p>
      </sec>
      <sec id="article-149610.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=149610&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=149610">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/149610/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=149610">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-149610.s9">
        <title>References</title>
        <ref id="article-149610.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Moy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moy</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Preventative Options and the Future of Chemoprevention for Cutaneous Tumors.</article-title>
            <source>Dermatol Clin</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>231</fpage>
            <page-range>231-238</page-range>
            <pub-id pub-id-type="pmid">36410981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asgari</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Moffet</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Quesenberry</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk Subgroups, 1998-2012.</article-title>
            <source>JAMA Dermatol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>151</volume>
            <issue>9</issue>
            <fpage>976</fpage>
            <page-range>976-81</page-range>
            <pub-id pub-id-type="pmid">26039887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kelley</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Prokop</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Dermatol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>152</volume>
            <issue>4</issue>
            <fpage>419</fpage>
            <page-range>419-28</page-range>
            <pub-id pub-id-type="pmid">26762219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guy</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Machlin</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Ekwueme</surname>
                <given-names>DU</given-names>
              </name>
              <name>
                <surname>Yabroff</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011.</article-title>
            <source>Am J Prev Med</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-187</page-range>
            <pub-id pub-id-type="pmid">25442229</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Olbricht</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Hartman</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Nicotinamide for Keratinocyte Carcinoma Chemoprevention: A Nationwide Survey of Mohs Surgeons.</article-title>
            <source>Dermatol Surg</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>452</fpage>
            <page-range>452-453</page-range>
            <pub-id pub-id-type="pmid">33625146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snaidr</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Damian</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Halliday</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety.</article-title>
            <source>Exp Dermatol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>28 Suppl 1</volume>
            <fpage>15</fpage>
            <page-range>15-22</page-range>
            <pub-id pub-id-type="pmid">30698874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forbat</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Al-Niaimi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Use of nicotinamide in dermatology.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-144</page-range>
            <pub-id pub-id-type="pmid">28052374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Targeting androgen receptor in macrophages inhibits phosphate-induced vascular smooth muscle cell calcification by decreasing IL-6 expression.</article-title>
            <source>Vascul Pharmacol</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>130</volume>
            <fpage>106681</fpage>
            <pub-id pub-id-type="pmid">32387336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Que</surname>
                <given-names>SKT</given-names>
              </name>
              <name>
                <surname>Zwald</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Schmults</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>249</fpage>
            <page-range>249-261</page-range>
            <pub-id pub-id-type="pmid">29332705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Pe&#x000f1;as</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dalziell</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>McKenzie</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Dhillon</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Vardy</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kricker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>St George</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chinniah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Halliday</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Damian</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Oct</month>
            <day>22</day>
            <volume>373</volume>
            <issue>17</issue>
            <fpage>1618</fpage>
            <page-range>1618-26</page-range>
            <pub-id pub-id-type="pmid">26488693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Dalziell</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>McKenzie</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Lowe</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Eris</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Dhillon</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Vardy</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bielski</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Halliday</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Damian</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients.</article-title>
            <source>Br J Dermatol</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>175</volume>
            <issue>5</issue>
            <fpage>1073</fpage>
            <page-range>1073-1075</page-range>
            <pub-id pub-id-type="pmid">27061568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Snaidr</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Eggins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Fernand&#x000e9;z-Pe&#x000f1;as</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sidhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paddon</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Banney</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Upjohn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schaider</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ganhewa</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McKenzie</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McLean</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lochhead</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ibbetson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dettrick</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Landgren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Allnutt</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Davenport</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Mumford</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stagg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tedman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gribbin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>De Rosa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Doolan</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Kok</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Kovitwanichkanont</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Dhillon</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Vardy</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chadban</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Bowen</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Damian</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Mar</month>
            <day>02</day>
            <volume>388</volume>
            <issue>9</issue>
            <fpage>804</fpage>
            <page-range>804-812</page-range>
            <pub-id pub-id-type="pmid">36856616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mainville</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smilga</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Fortin</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis.</article-title>
            <source>J Cutan Med Surg</source>
            <year>2022</year>
            <season>May-Jun</season>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>297</fpage>
            <page-range>297-308</page-range>
            <pub-id pub-id-type="pmid">35134311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKerrow</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>MacKie</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Lesko</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The effect of oral retinoid therapy on the normal human immune system.</article-title>
            <source>Br J Dermatol</source>
            <year>1988</year>
            <month>Sep</month>
            <volume>119</volume>
            <issue>3</issue>
            <fpage>313</fpage>
            <page-range>313-20</page-range>
            <pub-id pub-id-type="pmid">2972309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bellman</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Eaglstein</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Low dose isotretinoin in the prophylaxis of skin cancer in renal transplant patients.</article-title>
            <source>Transplantation</source>
            <year>1996</year>
            <month>Jan</month>
            <day>15</day>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>173</fpage>
            <pub-id pub-id-type="pmid">8560565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Good</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Nielson</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Use of Topical and Systemic Retinoids in Solid Organ Transplant Recipients: Update and Review of the Current Literature.</article-title>
            <source>Dermatol Surg</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>12</issue>
            <fpage>1442</fpage>
            <page-range>1442-1449</page-range>
            <pub-id pub-id-type="pmid">31403546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kraemer</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>DiGiovanna</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Moshell</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Tarone</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Peck</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin.</article-title>
            <source>N Engl J Med</source>
            <year>1988</year>
            <month>Jun</month>
            <day>23</day>
            <volume>318</volume>
            <issue>25</issue>
            <fpage>1633</fpage>
            <page-range>1633-7</page-range>
            <pub-id pub-id-type="pmid">3287161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moshell</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>Prevention of skin cancer in xeroderma pigmentosum with oral isotretinoin.</article-title>
            <source>Cutis</source>
            <year>1989</year>
            <month>May</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>485</fpage>
            <page-range>485-90</page-range>
            <pub-id pub-id-type="pmid">2721244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Oral Alitretinoin in Hand Eczema and Palmoplantar Pustulosis in Korean Patients.</article-title>
            <source>Ann Dermatol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-145</page-range>
            <pub-id pub-id-type="pmid">33911562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsai</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Aqui</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Vogl</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Bloom</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Nasta</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wasik</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene.</article-title>
            <source>Am J Transplant</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>2070</fpage>
            <page-range>2070-3</page-range>
            <pub-id pub-id-type="pmid">15996263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duvic</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Oral bexarotene for post-transplant cutaneous T-cell lymphoma.</article-title>
            <source>Dermatol Ther</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">28748653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Que</surname>
                <given-names>SKT</given-names>
              </name>
              <name>
                <surname>Zwald</surname>
                <given-names>FO</given-names>
              </name>
              <name>
                <surname>Schmults</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>78</volume>
            <issue>2</issue>
            <fpage>237</fpage>
            <page-range>237-247</page-range>
            <pub-id pub-id-type="pmid">29332704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knip</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Douek</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Gillmor</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>McLean</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Bingley</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>EA</given-names>
              </name>
              <collab>European Nicotinamide Diabetes Intervention Trial Group</collab>
            </person-group>
            <article-title>Safety of high-dose nicotinamide: a review.</article-title>
            <source>Diabetologia</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>43</volume>
            <issue>11</issue>
            <fpage>1337</fpage>
            <page-range>1337-45</page-range>
            <pub-id pub-id-type="pmid">11126400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khalil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bardawil</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stephan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Darwiche</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kibbi</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Nemer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kurban</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>684</fpage>
            <page-range>684-696</page-range>
            <pub-id pub-id-type="pmid">28318351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nohynek</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Meuling</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Vaes</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schulte</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Steiling</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bausch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gerber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sasa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nau</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Repeated topical treatment, in contrast to single oral doses, with Vitamin A-containing preparations does not affect plasma concentrations of retinol, retinyl esters or retinoic acids in female subjects of child-bearing age.</article-title>
            <source>Toxicol Lett</source>
            <year>2006</year>
            <month>May</month>
            <day>05</day>
            <volume>163</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-76</page-range>
            <pub-id pub-id-type="pmid">16243460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henning</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Conaway</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>UH</given-names>
              </name>
            </person-group>
            <article-title>Retinoid receptors in bone and their role in bone remodeling.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2015</year>
            <volume>6</volume>
            <fpage>31</fpage>
            <pub-id pub-id-type="pmid">25814978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Passi</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Butcher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Orme</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>JEA</given-names>
              </name>
              <name>
                <surname>Stoddard</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Crum</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Gouripeddi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Digre</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Increased Incidence of Pseudotumor Cerebri Syndrome Among Users of Tetracycline Antibiotics.</article-title>
            <source>J Neuroophthalmol</source>
            <year>2022</year>
            <month>Sep</month>
            <day>01</day>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>323</fpage>
            <page-range>323-327</page-range>
            <pub-id pub-id-type="pmid">35427251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <article-title>Incorrect Affilation.</article-title>
            <source>JAMA Dermatol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>152</volume>
            <issue>1</issue>
            <fpage>114</fpage>
            <pub-id pub-id-type="pmid">26762259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Altman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris.</article-title>
            <source>Dermatology</source>
            <year>2002</year>
            <volume>204</volume>
            <issue>3</issue>
            <fpage>232</fpage>
            <page-range>232-5</page-range>
            <pub-id pub-id-type="pmid">12037453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seitz</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Alcohol and retinoid metabolism.</article-title>
            <source>Gut</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>748</fpage>
            <page-range>748-50</page-range>
            <pub-id pub-id-type="pmid">11076870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ludot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mouchabac</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferreri</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Inter-relationships between isotretinoin treatment and psychiatric disorders: Depression, bipolar disorder, anxiety, psychosis and suicide risks.</article-title>
            <source>World J Psychiatry</source>
            <year>2015</year>
            <month>Jun</month>
            <day>22</day>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>222</fpage>
            <page-range>222-7</page-range>
            <pub-id pub-id-type="pmid">26110123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Tope</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Effect of acitretin on wound healing in organ transplant recipients.</article-title>
            <source>Dermatol Surg</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>4 Pt 2</issue>
            <fpage>667</fpage>
            <page-range>667-73</page-range>
            <pub-id pub-id-type="pmid">15061853</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Euvrard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kanitakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Claudy</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Skin cancers after organ transplantation.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Apr</month>
            <day>24</day>
            <volume>348</volume>
            <issue>17</issue>
            <fpage>1681</fpage>
            <page-range>1681-91</page-range>
            <pub-id pub-id-type="pmid">12711744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Acuna</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Sutradhar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>NN</given-names>
              </name>
            </person-group>
            <article-title>Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada.</article-title>
            <source>JAMA Oncol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>463</fpage>
            <page-range>463-9</page-range>
            <pub-id pub-id-type="pmid">26746479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Euvrard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kanitakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pouteil-Noble</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dureau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Touraine</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Faure</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Claudy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thivolet</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>2 Pt 1</issue>
            <fpage>222</fpage>
            <page-range>222-9</page-range>
            <pub-id pub-id-type="pmid">7622649</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Webb</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Koffman</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre.</article-title>
            <source>Transplant Proc</source>
            <year>1997</year>
            <season>Feb-Mar</season>
            <volume>29</volume>
            <issue>1-2</issue>
            <fpage>828</fpage>
            <page-range>828-30</page-range>
            <pub-id pub-id-type="pmid">9123544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liddington</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Endre</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Venning</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Murie</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Skin cancer in renal transplant recipients.</article-title>
            <source>Br J Surg</source>
            <year>1989</year>
            <month>Oct</month>
            <volume>76</volume>
            <issue>10</issue>
            <fpage>1002</fpage>
            <page-range>1002-5</page-range>
            <pub-id pub-id-type="pmid">2597939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winkelhorst</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Brokelman</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Tiggeler</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Wobbes</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Incidence and clinical course of de-novo malignancies in renal allograft recipients.</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>409</fpage>
            <page-range>409-13</page-range>
            <pub-id pub-id-type="pmid">11417989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bavinck</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>De Boer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vermeer</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Hartevelt</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>van der Woude</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Claas</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Wolterbeek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vandenbroucke</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients.</article-title>
            <source>Br J Dermatol</source>
            <year>1993</year>
            <month>Sep</month>
            <volume>129</volume>
            <issue>3</issue>
            <fpage>242</fpage>
            <page-range>242-9</page-range>
            <pub-id pub-id-type="pmid">8286220</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kovach</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Sams</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Stasko</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Systemic strategies for chemoprevention of skin cancers in transplant recipients.</article-title>
            <source>Clin Transplant</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>726</fpage>
            <page-range>726-34</page-range>
            <pub-id pub-id-type="pmid">16313317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malesu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Scolyer</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>McKenzie</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Madore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Halliday</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Damian</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Nicotinamide for skin cancer chemoprevention: effects of nicotinamide on melanoma in vitro and in vivo.</article-title>
            <source>Photochem Photobiol Sci</source>
            <year>2020</year>
            <month>Feb</month>
            <day>19</day>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-179</page-range>
            <pub-id pub-id-type="pmid">31942903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goodson</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Cotter</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cassidy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wade</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Florell</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Boucher</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: towards a novel paradigm for melanoma chemoprevention.</article-title>
            <source>Clin Cancer Res</source>
            <year>2009</year>
            <month>Dec</month>
            <day>01</day>
            <volume>15</volume>
            <issue>23</issue>
            <fpage>7434</fpage>
            <page-range>7434-40</page-range>
            <pub-id pub-id-type="pmid">19920101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>O'Kelly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Leary</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Deady</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Dudley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rutledge</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>McCormick</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Houlihan</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Ni Raghallaigh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moloney</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Conlon</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.</article-title>
            <source>Ren Fail</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>607</fpage>
            <page-range>607-612</page-range>
            <pub-id pub-id-type="pmid">32605413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Euvrard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boissonnat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roussouli&#x000e8;res</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kanitakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Decullier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Claudy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sebbag</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients.</article-title>
            <source>Transpl Int</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>8</issue>
            <fpage>855</fpage>
            <page-range>855-7</page-range>
            <pub-id pub-id-type="pmid">19951373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tai</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Russ</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.</article-title>
            <source>Am J Transplant</source>
            <year>2012</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>1146</fpage>
            <page-range>1146-56</page-range>
            <pub-id pub-id-type="pmid">22420843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-149610.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yakupoglu</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Buell</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Woodle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.</article-title>
            <source>Transplant Proc</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>358</fpage>
            <page-range>358-61</page-range>
            <pub-id pub-id-type="pmid">16549120</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
